Antigen-specific immunotherapy of cervical and ovarian cancer
about
Adoptive immunotherapy against ovarian cancerMembrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumorsPapillomavirus prophylactic vaccines: established successes, new approaches.Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.Carrageenan as an adjuvant to enhance peptide-based vaccine potencyVaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancerPotential target antigens for a universal vaccine in epithelial ovarian cancer.Immunotherapy for ovarian cancer: what's next?Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Past, present and future targets for immunotherapy in ovarian cancerIn vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies.DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cellsCancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.p53 autoantibodies, cytokine levels and ovarian carcinogenesisLeveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineTargeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studiesTumour-associated antigens: considerations for their use in tumour immunotherapy.Dendritic cell immunotherapy in ovarian cancer.Automated, Miniaturized, and Integrated Quality Control-on-Chip (QC-on-a-Chip) for Cell-Based Cancer Therapy Applications
P2860
Q26748905-F781C4A5-C3A5-4A60-ABB4-6FF0BA2C2BE5Q30278773-F880A038-150C-4BD4-9EFC-76EE1B7AEAACQ33614425-1782C627-51D6-4495-89D7-E8240FC81C75Q34007762-2C45DCFC-060C-408B-B61F-C5787E32FB01Q34012257-CB9B48CF-5AA3-40B8-AA70-AF5B014E20E6Q34078674-8E3FFA7B-1F57-45B1-9CFE-A41CCD3AAB74Q34122828-4A9BC014-9B33-46F0-8DB3-31C516761095Q34159451-BB0C8A71-BF93-46A9-A1EC-DC54FFFDAF08Q34743514-B2121CDA-47D9-4595-A80E-0EDAD7344B9EQ34898280-701482AC-D9ED-4497-88B4-C69905931659Q35034010-61174449-A089-44E4-A59D-DB31539E4944Q35051712-5D344CAB-B9D4-4F9D-B4FD-3152B5FF6BE4Q35148074-2F3AC613-C610-4C82-B150-DBF63A8AF221Q35820674-077ED2F6-BCED-49F0-8E07-43B3C4861AE1Q37223836-3EA91F93-0952-41D1-B505-022E0C7D41DBQ37224420-5AD5FBC7-075C-42DC-A7BD-3C05303B1119Q37494787-297A705D-F2B4-4104-9A09-A6DB3DB369E6Q37848203-39D84E56-9C66-4499-9F33-1A2AD1C24B83Q38069183-9161EBA3-1E51-4686-854C-73EE53C4D039Q57901322-5B313F65-AE83-4059-AB70-91A6DD335B7F
P2860
Antigen-specific immunotherapy of cervical and ovarian cancer
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Antigen-specific immunotherapy of cervical and ovarian cancer
@ast
Antigen-specific immunotherapy of cervical and ovarian cancer
@en
Antigen-specific immunotherapy of cervical and ovarian cancer
@nl
type
label
Antigen-specific immunotherapy of cervical and ovarian cancer
@ast
Antigen-specific immunotherapy of cervical and ovarian cancer
@en
Antigen-specific immunotherapy of cervical and ovarian cancer
@nl
prefLabel
Antigen-specific immunotherapy of cervical and ovarian cancer
@ast
Antigen-specific immunotherapy of cervical and ovarian cancer
@en
Antigen-specific immunotherapy of cervical and ovarian cancer
@nl
P2093
P2860
P3181
P1476
Antigen-specific immunotherapy of cervical and ovarian cancer
@en
P2093
Archana Monie
Chien-Fu Hung
Richard Roden
P2860
P3181
P356
10.1111/J.1600-065X.2008.00622.X
P577
2008-04-01T00:00:00Z